05:27 PM EDT, 09/16/2025 (MT Newswires) -- Kura Oncology ( KURA ) said Tuesday it is hosting the first of two events for analysts and investors focused on its farnesyl transferase inhibitor, or FTI, program.

The event will feature preclinical data showing the potential of FTIs to improve the anti-tumor activity of targeted treatments in diverse tumor types, the company said.

The findings will provide context to interpret the preliminary data that will be presented next month at the ESMO Congress, Kura said.